<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pegylated recombinant human megakaryocyte growth and development factor (<z:chebi fb="77" ids="46793">PEG</z:chebi>-rHuMGDF) potently stimulates platelet production in humans, mitigates <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> associated with nonmyeloablative chemotherapy, and reduces the need for platelet transfusions </plain></SENT>
<SENT sid="1" pm="."><plain>Its long-term effect in patients, however, is not well understood </plain></SENT>
<SENT sid="2" pm="."><plain>We report a patient with aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> who received 3 cycles of <z:chebi fb="77" ids="46793">PEG</z:chebi>-rHuMGDF 3 times a week for up to 2 years </plain></SENT>
<SENT sid="3" pm="."><plain>Platelet counts slightly increased 1 week after the initiation of <z:chebi fb="77" ids="46793">PEG</z:chebi>-rHuMGDF therapy, <z:mp ids='MP_0001914'>bleeding</z:mp> episodes decreased, and there was no need for platelet transfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of <z:chebi fb="77" ids="46793">PEG</z:chebi>-rHuMGDF increased not only platelet numbers but also reticulocyte counts, and reduced the need for erythrocyte transfusions as well </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant adverse events, and no neutralizing antibodies were detected in the patient </plain></SENT>
</text></document>